diff --git a/projects/_posts/2023-11-01-secondary-metabolism.md b/projects/_posts/2023-11-01-secondary-metabolism.md
index 7663146d..95174e76 100644
--- a/projects/_posts/2023-11-01-secondary-metabolism.md
+++ b/projects/_posts/2023-11-01-secondary-metabolism.md
@@ -31,7 +31,8 @@ The production of secondary metabolites, including antibiotics, may give bacteri
 Another important aspect of microbial secondary metabolism concerns the biotransformation of xenobiotics. Gut bacterial xenobiotic metabolism has been known to also affect some human medications. In our research we aim to decipher how gut bacteria alter exposure to immunosuppressive drugs in kidney transplant patients. Using both reductionistic experimental studies and extensive clinical trials, our team combines bioinformatics, experimental techniques, and clinical insights. With this multidisciplinary approach we are unravelling the complex drug-bacterial interactions to predict how each patient with their individual-specific gut microbiome responds distinctly to the same medication. Ultimately, we aim to translate these insights to move towards more personalised immunosuppressive therapies with improved efficacy and safety.
 
 ## Ongoing clinical trials  
-[PRISMA Trial](https://drks.de/search/de/trial/DRKS00023398) : The role of the gut microbiome in kidney transplantation–Towards personalized immunosuppression
-[Pro-Tac Trial](https://classic.clinicaltrials.gov/ct2/show/NCT06057545?term=pro-tac&cntry=DE&draw=2&rank=1): Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation 
+
+- [PRISMA Trial](https://drks.de/search/de/trial/DRKS00023398) : The role of the gut microbiome in kidney transplantation–Towards personalized immunosuppression
+- [Pro-Tac Trial](https://classic.clinicaltrials.gov/ct2/show/NCT06057545?term=pro-tac&cntry=DE&draw=2&rank=1): Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation